Medical Device Clinical Trials: A Comprehensive FAQ and Guide

IDE, 510(k), De Novo, PMA | Pilot and Feasibility Studies | Pivotal Trials | Post-Market and Registry Studies

This page is a practitioner-level reference for medical device clinical trials, created by Emergent CRO, a contract research organization (CRO) specializing exclusively in medical device clinical development. Whether you are a startup founder planning your first-in-human study, an established manufacturer designing a pivotal trial, or an investor evaluating a medtech opportunity, this guide covers the regulatory pathways, trial design considerations, cost and timeline benchmarks, and operational best practices you need.

Emergent CRO helps medical device companies navigate clinical trials across therapeutic areas including cardiovascular, orthopedic, neurological, diagnostic, digital health, and AI/ML-based devices. Our expertise spans Pilot Studies, Early Feasibility Studies (EFS), traditional feasibility trials, pivotal studies, IDE submissions, 510(k) clearances, De Novo classifications, PMA approvals, Post-Market and Registry trials.

Use this table to quickly identify which FDA pathway applies to your medical device. Detailed explanations follow.

Pathway

Device Class

Predicate Required?

Clinical Data

Typical Timeline

510(k)

Class II

Yes

10-15% require clinical

3-6 months

De Novo

Novel Class

No (creates new type)

Usually required

6-12 months

PMA

Class III

No

Pivotal trial required

1-3+ years

IDE (for trials)

Significant Risk

N/A

Enables clinical study

30-day FDA review

Quick Reference: EU CEMarking Pathways at a Glance

Use this table to quickly identify which pathway applies to your medical device. Detailed explanations follow.

Medical Devices (EU MDR 2017/745)

Conformity Assessment Route

Device Class

Notified Body Required?

Clinical / Performance Data

Typical Timeline*

SelfCertification

Class I (nonsterile, nonmeasuring)

No

Clinical evaluation (often literaturebased)

~3–6 months

NB Review – Limited Scope

Class I (sterile / measuring / reusable surgical)

Yes (limited)

Clinical evaluation required

~6–9 months

NB Full Conformity Assessment

Class IIa

Yes

Clinical evaluation; may include clinical data

~9–15 months

NB Full Conformity Assessment

Class IIb

Yes

Clinical evaluation; clinical data often required

~12–18 months

NB Full + Expert Review

Class III

Yes (+ expert panel consult in some cases)

Clinical investigation typically required

~18–24+ months

In Vitro Diagnostics (EU IVDR 2017/746)

Conformity Assessment Route

IVD Class

Notified Body Required?

Performance Data Required

Typical Timeline*

SelfCertification

Class A (nonsterile)

No

Scientific validity + analytical performance

~3–6 months

NB – Sterility Only

Class A (sterile)

Yes (sterility only)

Performance evaluation

~6–9 months

NB Full Assessment

Class B

Yes

Performance evaluation

~9–15 months

NB Full + Design Review

Class C

Yes

Performance evaluation; clinical performance often required

~12–18 months

NB Full + Batch / Reference Lab Review

Class D

Yes

Extensive performance & clinical evidence

~18–24+ months

Medical Device Clinical Trial Phases

Medical device trials typically progress through these phases:

  • Pilot, First in Human and Early Feasibility Study (EFS): First-in-human, typically <10 participants. Tests basic safety and device functionality. FDA encourages EFS for novel devices.
  • Traditional Feasibility Study: 10-30 participants at 1-3 sites. Refines device design and clinical protocol before pivotal.
  • Pivotal Trial: 50-300+ participants at 5-30 sites. Generates statistically significant evidence for FDA submission.

Key Terms Glossary

Understanding these terms is essential for navigating medical device clinical development:

Term

Definition

IDE (Investigational Device Exemption)

FDA authorization required to conduct clinical trials with a significant risk investigational device in the United States.

IRB (Institutional Review Board)

Independent ethics committee that reviews and approves clinical research protocols to protect study participants.

GCP (Good Clinical Practice)

An international ethical and scientific quality standard for the design, conduct, recording, and reporting of clinical trials that involve human participants, intended to protect the rights, safety, and wellbeing of trial participants and to ensure the credibility and reliability of clinical trial data.

Pre-Submission (Pre-Sub)

Formal FDA meeting (Q-Submission program) to get feedback on regulatory strategy, study design, or submission plans before filing.

Predicate Device

A legally marketed device to which a new device is compared to establish substantial equivalence in a 510(k) submission.

Pivotal Trial

The definitive clinical study designed to provide statistically significant evidence of safety and effectiveness for regulatory approval.

Feasibility Study

Early-stage clinical trial (first-in-human or pilot) to assess device safety, functionality, and proof of concept before pivotal.

CEC (Clinical Events Committee)

An independent, blinded panel of clinical experts that reviews and adjudicates prespecified clinical events or endpoints in a clinical trial using standardized definitions to ensure objective, consistent, and unbiased assessment.

DSMB (Data Safety Monitoring Board)

Independent committee that monitors participant safety and reviews interim data during clinical trials.

SaMD (Software as a Medical Device)

Software intended for medical purposes that performs its function without being part of a hardware medical device.

EFS (Early Feasibility Study)

FDA program allowing first-in-human studies with typically fewer than 10 participants to assess novel device concepts.

EDC (Electronic Data Capture)

A system for the electronic collection, management, and storage of clinical trial data, typically via electronic case report forms.

FDA

Food and Drug Administration – United States

HC

Health Canada – Canada

MHLW

Ministry of Health, Labour and Welfare – Japan

NMPA

National Medical Products Administration – China

PMDA

Pharmaceuticals and Medical Devices Agency – Japan

NB

Notified Body – EU

TGA

Therapeutic Goods Administration – Australia

TUV

Technischer Überwachungsverein (Technical Inspection Association) – Germany

This section addresses foundational questions about moving from device concept to first-in-human clinical testing.

Do I need a feasibility study before submitting an IDE or starting a first-in-human trial?

Early feasibility studies (often first-in-human trials) are not strictly mandatory, but they are highly recommended in most cases. A well-designed feasibility study de-risks your program by providing initial human data on safety and device functionality before you invest in a larger pivotal trial.

The FDA encourages Early Feasibility Studies (EFS) for novel devices through its EFS program. These are limited-scale clinical studies (typically fewer than 10 participants) that provide proof of principle and initial safety insights.

When to conduct a feasibility study: If your device is high-risk, innovative, or lacks substantial predicate data, conducting a small feasibility/pilot trial is usually wise. It allows you to identify unanticipated issues in a controlled setting and make design or protocol refinements before committing to a larger pivotal trial.

Emergent CRO recommendation: Plan for a pilot study whenever you are introducing a novel device to humans. It serves as an insurance policy for your clinical and regulatory strategy, providing FDA reviewers and investors comfort that the device has initial human data. Also, use the FDA’s pre-submission process early to introduce the technology and gather their feedback on the pathway.

How do I determine whether my device concept is clinically viable?

Assessing clinical viability means confirming that your device can solve a real problem in participant care safely and effectively. The key steps include:

  • Identify the unmet clinical need: Is there a clear medical problem lacking good solutions? Engage clinicians early and obtain frank feedback on your concept.
  • Evaluate preclinical results in clinical context: If bench tests show the device improves precision by 20%, what clinical outcome does that improve? Map engineering benchmarks to clinical outcomes.
  • Study the standard of care and competitors: Can your device fit into clinical workflows without significant disruption? Consider procedure time, learning curve, and hospital infrastructure compatibility.
  • Conduct simulated use testing: Cadaver labs or realistic simulations with clinicians can pressure-test the device before human trials.

Emergent CRO helps clients validate clinical viability by organizing clinician advisory boards and early feasibility testing.

Benefits of early KOL involvement: Key opinion leaders who have input in development are more likely to become your investigators and advocate for the device. Investors and regulators view clinician involvement as a sign of credibility.

Emergent CRO facilitates these collaborations by leveraging our network of medical experts across therapeutic areas.

How do I assess whether my device solves a real, unmet clinical need?

Determining if your device addresses an unmet need requires honest assessment of the clinical landscape:

  • Identify the specific problem: For example, participants with condition “X” lack a minimally invasive treatment, leading to “Y” poor outcomes.
  • Confirm recognition by the medical community: Conduct clinician interviews, survey literature, and talk to advocacy groups.
  • Score the need: Consider factors like severity of the clinical issue, number of participants affected, and limitations of existing options.
  • Test clinician enthusiasm: Ask physicians: If this device works as intended, would it change how you treat participants? Enthusiastic responses are a green flag.

You know your device addresses a true unmet need when experts say, Can I have this now?

The type and amount of clinical evidence needed depends on your device’s risk classification and novelty:

Class II devices (510(k)): Many rely mostly on bench and animal testing. FDA requires clinical data in only about 10-15% of 510(k) submissions, typically when the device has novel technology or questions that bench data cannot answer.

De Novo devices: If your device is truly novel with no predicate, FDA will expect enough clinical evidence to reasonably assure safety and effectiveness for Class II classification, often a moderately sized pivotal study.

Class III devices (PMA): The gold standard is a pivotal clinical trial (or trials) similar to drug Phase III studies. This typically means 100+ participants, sometimes several hundred, with statistically significant endpoints.

Emergent CRO works with sponsors to determine the right evidence package early, ensuring that by submission time you have the data regulatory agencies expect for your device type.

Involve clinicians from day one. Early engagement might include informal discussions about the clinical need, formal advisory board meetings, or having a clinician as a co-inventor.

From a clinical trial perspective, early clinician input helps you define meaningful endpoints and study design. They can tell you what improvements would be considered clinically significant in practice.

Benefits of early KOL involvement: Key opinion leaders who have input in development are more likely to become your investigators and advocate for the device. Investors and regulators view clinician involvement as a sign of credibility.

Emergent CRO facilitates these collaborations by leveraging our network of medical experts across therapeutic areas.

Effective trial design is the foundation of regulatory success. This section covers critical planning decisions.

What are the biggest risks that derail medical device clinical trials?

Early-stage device trials can be derailed by several common risks:

  • Failure to demonstrate efficacy: The primary reason trials fail, often due to flawed study design or underpowered sample sizes.
  • Safety problems: Unanticipated adverse device effects can stop a trial. Thorough preclinical testing and gradual ramp-up with interim safety reviews help reduce this risk.
  • Poor participant enrollment: More than 10% of sites enroll zero participants. Overestimating enrollment capability is a top reason studies fail.
  • Regulatory non-compliance: Failing to adhere to GCP or the investigational plan can compromise data integrity.
  • Financial constraints: Trial delays can burn through funding faster than anticipated.
  • Mid-trial design changes: Device modifications during a trial can confound results and require regulatory amendments.

Emergent CRO’s approach focuses on risk mitigation, helping identify and plan for these pitfalls upfront. Using our years of expertise can shortcut additional development years and lost financial investment.

How do I estimate realistic participant enrollment for my device trial?

Accurate enrollment projection combines data analysis and site assessment:

  • Survey investigators: Ask how many eligible participants they see per month, applying realistic inclusion/exclusion criteria.
  • Discount optimism: Industry data shows around 11% of sites enroll no participants, and many enroll far fewer than expected.
  • Use historical data: Look at similar studies in clinical trial registries for enrollment benchmarks.
  • Account for screen failures: You may need to screen 2-3x the number of participants you intend to enroll.
  • Build in buffer: Plan for 20-40% fewer enrollments than sites estimate.

Emergent CRO utilizes a feasibility process as well as historical trial data from our internal database of site performance metrics as well as a qualification process to improve your enrollment outcomes early in the process.

Should I start my first medical device study in the U.S. or internationally?

This strategic decision involves regulatory and practical trade-offs:

Starting in the U.S.: Engages FDA early, generates data valued by U.S. investors, and the EFS program allows first-in-human trials under an IDE. However, U.S. trials have more regulatory overhead and higher costs.

Starting internationally: Europe, Australia, or other regions may offer faster first-in-human timelines or fewer upfront regulatory hurdles. FDA accepts well-conducted foreign clinical data if it meets GCP standards, but there is no guarantee.

Hybrid approach: Many sponsors do a small first-in-human trial abroad to get safety data, then conduct a formally FDA-reviewed study in the U.S.

Your specific device risk profile, resources, and strategic markets will guide the decision. Emergent CRO recommends engaging the FDA through the pre-submission process to clearly identify the optimal process and assists clients in evaluating the potential trade-offs.

When is a medical device ready for first-in-human testing?

Technology readiness can be assessed by these indicators:

  • Completed bench testing: Functional testing in conditions simulating the human body, stress tests, reliability testing. The device should be technically stable.
  • Positive safety assessments: Biocompatibility testing (ISO 10993), electrical safety, comprehensive risk analysis (ISO 14971), and typically at least one animal study for high-risk devices.
  • Usability validation: The device has been evaluated by clinicians in simulated environments with major usability issues resolved.
  • Regulatory readiness: You can compile required information (design, manufacturing, preclinical data) for an IDE submission.

You are ready for first-in-human when the device consistently performs as expected, preclinical safety data is positive, and additional bench testing would yield diminishing returns.

What is the difference between an early feasibility study and a pivotal trial?

These represent different stages with different purposes:

Characteristic

Early Feasibility Study

Pivotal Trial

Purpose

Proof of concept, initial safety

Definitive evidence for approval

Sample Size

Typically <10 participants

50-300+ participants

Endpoints

Device performance, acute safety

Clinical outcomes, statistical significance

Flexibility

Allows device/protocol modifications

Rigid, pre-specified protocol

Statistical Power

Descriptive, not powered

Powered to detect meaningful differences

Feasibility de-risks and informs design; pivotal provides the proof for regulatory approval.

Single-site vs multi-site pilot studies: How do I decide?

Single-site advantages: Tight control, consistent technique, easier coordination, faster enrollment for small N, cleaner data. Best for first-in-human or very novel devices where you need close feedback loops.

Multi-site advantages: Preview of broader usability, tests different operators and settings, builds a network of early adopters. Helps uncover issues that one expert site might miss.

Hybrid approach: Start with one site for the first few cases, then expand to 2-3 additional sites once initial safety is confirmed.

Understanding FDA regulatory pathways is essential for efficient device development. This section explains the differences and how to determine which pathway applies to your device.

What is the difference between 510(k), De Novo, PMA and HDE?

The right FDA pathway depends on your device’s risk classification and novelty:

510(k) Premarket Notification

Use when: Your device is Class II AND a substantially equivalent predicate device exists.

What it requires: Demonstrate your device is as safe and effective as the predicate through comparison of intended use, design, materials, and performance testing. Clinical data required in only 10-15% of cases.

Timeline: Typically 3-6 months for FDA review.

Outcome: FDA clears the device for marketing.

De Novo Classification

Use when: Your device is novel (no predicate) BUT poses low-to-moderate risk.

What it requires: Evidence demonstrating safety and effectiveness with general controls (and possibly special controls). Clinical data usually required.

Timeline: Typically 6-12 months for FDA review.

Outcome: FDA grants the request, creating a new device classification. Your device becomes a predicate for future 510(k)s.

PMA (Premarket Approval)

Use when: Your device is Class III (high-risk, life-supporting, or life-sustaining).

What it requires: Full scientific evidence of safety and effectiveness from well-controlled clinical trials. Most rigorous pathway and can be done using a modular approach.

Timeline: Typically 1-3+ years including clinical trials and FDA review.

Outcome: FDA approves the device for marketing.

Decision framework: If Class II with predicate, use 510(k). If Class II without predicate (novel), use De Novo. If Class III (high-risk), use PMA.

Emergent CRO conducts regulatory assessments early to confirm the likely pathway and can engage FDA to validate your strategy.

HDE (Humanitarian Device Exemption)

Use when: The device targets a rare disease or condition (≤8,000 patients/year in the U.S.) and the traditional PMA-level effectiveness evidence is impractical.

What it requires: Full scientific evidence of safety and effectiveness from well-controlled clinical trials. Most rigorous pathway and can be done using a modular approach.

Timeline: Typically 4-6 months for FDA review.

Outcome: FDA approves the device for the approved humanitarian indication. Effectiveness not established (must be stated in labeling) and IRB approval required at each institution prior to use.

.

Decision framework: If Class II with predicate, use 510(k). If Class II without predicate (novel), use De Novo. If Class III (high-risk), use PMA. If it is in a rare disease or condition, consider HDE.

Emergent CRO conducts regulatory assessments early to confirm the likely pathway and can engage FDA to validate your strategy.

An Investigational Device Exemption (IDE) is FDA’s authorization to conduct clinical trials with an investigational device.

Significant Risk (SR) devices: You MUST obtain IDE approval from FDA before starting any clinical trial. SR devices include implants, life-supporting devices, or devices that could cause serious harm. FDA reviews the IDE within 30 days.

Non-Significant Risk (NSR) devices: You can proceed with IRB approval alone. The IRB determines whether the device is NSR and serves as oversight. No FDA submission required, but you must follow abbreviated IDE requirements.

If there is any doubt about risk classification, seek FDA’s opinion through a Q-Submission. Conducting a trial without proper IDE authorization is a serious regulatory violation.

Pre-Submission meetings (Pre-Subs) are valuable opportunities to get FDA feedback. Request a Pre-Sub when:

  • Before finalizing pivotal trial design: Confirm your endpoints, sample size, control group, and follow-up duration meet FDA expectations.
  • Before IDE submission: Get feedback on protocol elements to avoid delays in IDE approval.
  • For regulatory pathway clarification: Confirm whether your device is 510(k), De Novo, or PMA.
  • When you have significant uncertainties: Any major questions that FDA input could clarify.

Plan the request 3-6 months before you need to make decisions. FDA typically provides written feedback within 70 days.

Emergent CRO helps clients formulate Pre-Sub questions and packages to maximize the value of FDA interactions.

Understanding realistic budgets and timelines is essential for planning and fundraising.

How much does a medical device clinical trial cost?

Costs vary significantly based on study type, participant numbers, sites, and device complexity:

Feasibility Study Costs (10-30 participants, 1-3 sites)

Typical range: $500,000 to $5 million

  • Simple device studies with short follow-up: Lower end
  • Implantable devices with longer monitoring: Higher end

Pivotal Trial Costs (50-300+ participants, 5-30 sites)

Typical range: $5 million to $15 million+

Key cost drivers include:

  • Number of participants and sites
  • Length of follow-up (some trials require up to 2-year follow-up for primary analysis)
  • Site selection increases cost considerations (private practice vs. academic centers)
  • Complexity of data collection and monitoring
  • Need for independent safety and endpoint adjudication
  • Regulatory submission support

Budget Categories to Plan

  • Site costs: startup, IRB fees, investigator fees, coordinator time
  • Management fees
  • Data management and biostatistics
  • Regulatory preparation (IDE, Pre-Subs)
  • Device manufacturing for trial use
  • Adverse event adjudication
  • Contingency buffer: 15-20% of total budget

Emergent CRO provides transparent pricing and helps clients develop realistic budgets based on protocol requirements.

How long does a medical device clinical trial take?

Early Feasibility Study Timeline: 12-18 months total

  • IDE preparation and approval: 3-4 months
  • Site startup: 2-3 months
  • Enrollment and follow-up: 6-9 months
  • Analysis and reporting: 2-3 months

Pivotal Trial Timeline: 2-4 years total

  • Pre-Sub and FDA feedback: 4-6 months
  • IDE preparation and approval: 4-6 months
  • Multi-site startup: 3-6 months
  • Enrollment: 12-24 months (highly variable)
  • Follow-up: As required and variable (6-60 months post-enrollment depending on safety considerations)
  • Database lock and analysis: 3-6 months
  • Submission and FDA review: 6-12 months

What causes medical device clinical trial delays?

Understanding common delays helps you plan mitigation strategies:

  • Enrollment challenges (most common): Sites overestimate participant availability, competing trials draw from the same pool, strict criteria limit eligibility.
  • Site startup delays: IRB approval timelines, contract negotiations, and staff training can add months.
  • Incorrect or incomplete team structure: Utilizing the incorrect team structure to manage the study activities which cause time delays and cost increases.
  • Unclear plan to successfully navigate the process: Using a patchwork of resources that are not optimized for successful study execution.
  • Protocol amendments: Changes requiring re-approval add time.
  • Device/manufacturing issues: Supply delays or quality problems interrupt enrollment.
  • Data quality issues: Query resolution can delay database lock.

Selecting the right CRO partner is critical. Evaluate these factors:

  • Device-specific expertise: Device trials differ significantly from drug trials. Look for demonstrated experience in your device type, understanding of FDA device regulations, and familiarity with device-specific challenges.
  • Regulatory capabilities: Can they support Pre-Subs, IDE preparation, and marketing applications? Ask about their FDA interaction track record.
  • Operational capabilities: Evaluate site network, project management approach, data management systems, and quality oversight.
  • Cultural fit: You will work closely for months or years. Assess responsiveness, transparency, and alignment with your company culture.

Emergent CRO specializes exclusively in medical devices and offers focused expertise that device companies need.

Specialized device types require tailored regulatory approaches.

How does FDA regulate AI and machine learning medical devices?

Software and AI-based medical devices (SaMD) have unique regulatory considerations:

Software validation: Emphasis on demonstrating the software is reliable, follows quality processes (IEC 62304), and includes robust documentation.

Algorithm adaptability: If your AI is locked (static), validate it like any software. If adaptive/continuously learning, FDA’s current approach requires considering changes as needing new submissions unless you outline a change control plan.

Clinical validation: You must show not just analytical accuracy but clinical impact. Reader studies may be needed to demonstrate physicians using the AI perform better.

Bias and subgroup performance: FDA expects analysis across demographics (age, ethnicity, scanner types) to ensure the algorithm is not narrowly trained.

Cybersecurity: Network-connected or cloud-based devices require threat modeling, cybersecurity controls, and plans for updates/patches.

How do combination products (device + drug) affect regulatory planning?

Combination products involve multiple FDA centers and overlapping regulations:

Primary jurisdiction: Determined by primary mode of action (PMOA). If the drug’s action is primary, CDER leads; if the device is primary, CDRH leads.

Integrated requirements: Clinical trials may need to collect data on both drug-related effects (PK, systemic safety) and device performance. Additional studies like animal toxicology for the drug component may be required.

Coordinated review: Engage the Office of Combination Products (OCP) at FDA to clarify the regulatory path and coordinate between centers.

IND considerations: You may need both an IDE and an IND, even if the device is the primary PMOA.

How do diagnostic devices differ from therapeutic devices in regulatory strategy?

In vitro diagnostics (IVDs) have different evidence requirements:

Evidence focus: Diagnostics prove value through accuracy and reliability of information, not direct participant outcomes. Key metrics are sensitivity, specificity, and positive/negative predictive value.

Study design: Compare test results to a gold standard or clinical truth, often with retrospective samples. Not typically randomized participant trials.

Analytical vs clinical validation: Must demonstrate both analytical performance (precision, reproducibility) and clinical performance (how well results correlate with clinical condition).

Different review divisions: IVDs are reviewed by FDA’s Office of In Vitro Diagnostics. Companion diagnostics may require CDER coordination.

Based on our experience, avoid these pitfalls:

  • Starting trials before device design is finalized, leading to mid-trial modifications and additional data requirements
  • Underestimating time and resources for regulatory preparation
  • Choosing the wrong regulatory pathway based on incomplete predicate analysis
  • Designing underpowered trials or using endpoints FDA will not accept
  • Failing to engage clinicians early, resulting in devices that do not fit clinical workflows
  • Overestimating site enrollment and underestimating startup timelines
  • Not building sufficient contingency into budgets and timelines

What happens after FDA approval or clearance?

FDA clearance or approval is not the end of regulatory obligations:

Post-market surveillance: For higher-risk devices, FDA may require post-approval studies to gather additional safety and effectiveness data in larger, more diverse populations.

Adverse event reporting (MDRs): Manufacturers must report adverse events and device malfunctions to FDA. Serious events have specific reporting timeframes.

Reimbursement: FDA clearance/approval (or EU CE marking) allows a product to be legally marketed, but payers separately decide whether they will cover, code, and pay for its use. These decisions are made after and independent of regulatory authorization.

Quality system compliance: Ongoing compliance with Quality System Regulation (21 CFR Part 820), including design controls, manufacturing controls, and CAPA procedures.

Labeling and promotion: All marketing must be consistent with cleared/approved indications. Off-label promotion is prohibited.

How do I plan for global regulatory submissions (CE marking and international)?

Consider international requirements early in development:

EU MDR (Medical Device Regulation) / EU In Vitro Diagnostic Regulation (IVDR): Stricter requirements than prior CE marking, including more rigorous clinical evidence, increased post-market surveillance, and Notified Body involvement.

Other major markets: Canada (Health Canada), Japan (PMDA), Australia (TGA), and China (NMPA) each have their own requirements. Some accept FDA or CE data to varying degrees.

Global clinical trials: Designing a single trial that meets multiple regulatory bodies’ requirements is more efficient than separate studies. Requires understanding each authority’s expectations upfront.

Emergent CRO helps clients develop global regulatory strategies that maximize efficiency while meeting each market’s requirements.

Understanding investor expectations helps you prepare for fundraising conversations.

What data do investors expect before funding a clinical program?

Sophisticated MedTech investors want to see the opportunity has been de-risked:

Proof-of-Concept Data

  • Robust bench testing and preclinical studies (animal or cadaver) demonstrating device functionality and safety
  • First-in-human or pilot clinical data, even a small case series, is a major asset
  • Startups that are clinical trial ready with documented results instill investor confidence

Clear Regulatory Pathway

  • Articulate whether your device is Class II or III
  • Explain why it is 510(k), De Novo, or PMA
  • Show timeline to clearance/approval
  • Ideally, demonstrate FDA feedback (Pre-Sub) supporting your plan

Market Validation

  • “De-risking” the asset through commercial data
  • Survey data from physicians indicating strong interest
  • Epidemiology data supporting participant population size
  • Letters of intent from hospitals or partnerships with leading clinics
  • Key clinicians on your advisory board

Investors favor startups that demonstrate a strong handle on regulatory steps and have clinical or real-world validation. Emergent CRO works with clients to assemble this evidence for compelling investor presentations.

How do I build investor confidence in my clinical program?

Key strategies include:

  • Early regulatory engagement: FDA Pre-Sub feedback shows you understand the pathway and have agency buy-in.
  • Clinician champions: KOLs on your advisory board who will advocate for the technology.
  • Realistic projections: Honest timelines and budgets based on industry benchmarks, not overly optimistic assumptions.
  • Risk mitigation plan: Demonstrate you have identified risks and have contingency plans.
  • CRO partnership: Working with an experienced device CRO signals operational readiness.

Work With Emergent CRO

Emergent CRO partners with medical device companies at every stage of clinical development, from early feasibility planning through pivotal trials and regulatory submission. Our specialized focus on medical devices means you get a team that understands the unique challenges of device development.

  • Clinical trial design and protocol development
  • FDA regulatory strategy and Pre-Submission support
  • IDE preparation and submission
  • Site selection, activation, and management
  • Clinical operations and monitoring
  • Data management and biostatistics
  • 510(k), De Novo, and PMA submission support
  • Post-market study design and execution

We support medical device trials across:

  • Cardiovascular devices
  • Orthopedic implants and instruments
  • Neurovascular devices
  • Diagnostic and imaging devices
  • Digital health and AI/ML-based SaMD
  • Surgical instruments and robotics
  • Combination products (device + drug)
  • Dermatology devices
  • Endocrinology devices
  • ENT devices
  • General surgery devices
  • Hematology diagnostics
  • Oncology devices and diagnostics
  • Pain Management devices
  • Plastics and Reconstruction Devices
  • Radiology devices
  • Spine devices
  • Sports Medicine devices
  • Trauma And Extremities devices
  • Urology devices

Do the Right Thing, Always. Integrity is non-negotiable. We do the right thing, even when no one is watching. We’re honest, transparent, and committed to delivering on our word. Our reputation is built on trust, and that trust is earned everyday through our consistent acts of integrity. 

Own it, Deliver it. Excellence doesn’t happen by chance—it’s achieved through effort, innovation, accountability, and perseverance. We treat each medical technology that we work with as if it’s our own and we act as an extension of our client’s team. We take pride in the quality of our service, develop the plan with the highest standards, and execute that plan with the same care and dedication as if we had designed the technology ourselves. That level of ownership is helping us redefine what a CRO can be. 

Commitment to Continuous Growth. We’re always learning, improving, and pushing ourselves to be better than we were yesterday. Challenges aren’t roadblocks—they’re opportunities. We embrace kind, constructive feedback, seek knowledge, and adapt to change because we know that growth is the key to our long-term personal and professional success. But growth doesn’t just happen—it’s intentional. 

Solutions over Problems. Our work is complex and often brings challenges. We choose to focus on the solutions, not the problems. We support one another, lift each other up, and tackle obstacles with confidence. No matter what comes our way, we find a way forward with energy, optimism, and determination because that’s what sets us apart from the rest.

Built to care

. . . about each other

. . . about creating a healthier tomorrow for the world

. . . about our client’s success

. . . about leaving things better than we found them

. . . about redefining what a CRO can be

We operate as an extension of your team. We guarantee partnership, direct access to our CEO and leadership team, and practical solutions to bring your medical innovation to market.

At Emergent CRO, We’re Built Differently (our three uniques)

True Collaboration.  Relationships, not transactions 

Focus on What Matters Most. Delivering high-quality work at startup speed 

Value from Start to Finish. Transparent, value-based pricing

Ready to discuss your medical device clinical trial? Contact Emergent CRO for a consultation.